CytoDyn Announces Webcast to Provide Company Update
07 déc. 2023 16h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
21 nov. 2023 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
November 2023 Letter to Shareholders
03 nov. 2023 16h02 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of...
CytoDyn Announces Company Updates and Investment Community Update Webcast
11 juil. 2023 16h05 HE
|
CytoDyn Inc.
Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24th, 2023, at 1 PM PT / 4 PM ET ...
CytoDyn Announces President Takes Medical Leave of Absence
24 mai 2023 17h05 HE
|
CytoDyn Inc.
Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor VANCOUVER, Washington,...
CytoDyn to Hold Webcast to Provide a Company Update
05 avr. 2023 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
23 déc. 2022 08h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
22 nov. 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
28 oct. 2022 17h15 HE
|
CytoDyn Inc.
Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology indications Webcast to be held Monday, October 31, 2022, at 5:30...
CytoDyn Announces Appointment of Additional Directors with Industry Experience
20 oct. 2022 08h30 HE
|
CytoDyn Inc.
Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board VANCOUVER, Wash., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY)...